COSMOS · Curved Optoelectronic System to Monitor Ocular Signals
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2022-09-01 → 2024-08-31
- EU contribution
- €172,750
- Participants
- 2
- Scheme
- HORIZON-TMA-MSCA-PF-EF
Lines connect the coordinator with its partners.
Results in brief
Curved Optoelectronic System to Monitor Ocular Signals
The COSMOS project vision targeted the broad field of bioelectricity beyond cellular excitability, advancing the path toward bioelectricity-based theranostics. This field, also known as bioelectronic medicine, aims at unravelling the fundamental role of bioelectricity in homeostatic regulation of key life processes happening at the cellular and tissue scales, and develop translatable technologies for critical areas of medical research, including wound healing, cancer, ageing, and morphogenesis. Endogenous electric fields (EFs) play a crucial role both in cell development and pathology. The directional migration of cells in an EF is known as galvanotaxis and represents a dominant mechanism in guiding the behaviour of multiple cell populations in mammals, fishes, amphibians, and plants. EF perturbations induce localized bioelectrical changes which trigger different cell responses, such as mitosis, migration, and mutation. Naturally occurring EFs can be altered by pharmacological administration to foster different cellular responses. For example, upon manipulating the EF in wounds, epithelial cells follow the direction of the signal, promoting or inhibiting corneal regeneration based on EF polarity. Another key example in the field of cancer biology regards the employment of tumor treating fields (TTFs) and electroceuticals acting on dysregulated ion channels in cellular membranes. Regenerative medicine and pharmaceutical strategies aim at restoring diseased or damaged tissues resulting from a range of conditions. However, their clinical translation remains a major challenge, due to the lack of knowledge on the mechanisms underlying these processes. This technological and knowledge gap has a high price for our healthcare systems. For example, medicare cost estimates for acute wound treatments are $28-$96 billion per year. In this scenario, technology can play two important roles: 1) Scientific Advancement: Knowledge as the Main Goal. Exploit existing microsystems to investigating bioelectricity beyond cellular excitability, and access unknown biological information by targeting unexplored applications. 2) Technological Advancement: Translation as the Main Goal. In parallel, existing technologies can be refined and improved to develop nanosystems that can interface living matter either non-invasively and with higher throughput, or probing biological signals unaccessible with current methods. In the context of COSMOS, preliminary steps were conducted in both directions in the fields of non-excitable cells bioelectricity, with a focus on epithelial cells and cancer cells.
Data: CORDIS, © European Union
Project objective
COSMOS is a highly multi-disciplinary project that will deliver the first technology for the continuous recording of cell resting membrane potentials. Biological electric fields arise by ion transport across cell membranes and tissues, and represent a crucial cue in guiding cellular differentiation (e.g., stem cells), mutation (e.g., cancer cells), and migration (e.g., wound healing). However, the underlying mechanisms behind these phenomena are yet to be fully discovered. This is because this data is currently hard to access with existing technologies: microelectrode arrays rely on electroporation (i.e. probing the cell membrane with consequent disruption, which makes it challenging to perform prolonged measurements), the patch-clamp method has a low throughput, and novel optical technologies mainly addressed the measurement of action potentials. However, most cells in the human body do not fire action potentials, and they communicate in a narrower electrical range. COSMOS will implement a platform to perform contact-free recordings of membrane potentials by optically mirroring the cell membrane charge. This technology will be first applied in testing corneal regenerative technologies (topical drugs, limbal stem cells, post-corneal transplant monitoring), as corneal wounds are an excellent model to study electric field-regulated cell behavior. COSMOS will provide the technological tool to enable addressing a fundamental scientific question, as well as pave the way towards new diagnostic methods, therapeutic strategies, and in vitro drug testing platforms.
Original text from CORDIS.
Participants
Links
Data: CORDIS, © European Union
